Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304552 | 0.87 | FDPS (0.43) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL14864693 | 0.87 | FDPS (0.43) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL304551 | 0.87 | FDPS (0.43) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL888803 | 0.84 | FDPS (0.41) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL10122821 | 0.84 | FDPS (0.41) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL8908145 | 0.83 | NLRP3 (0.42) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL15867490 | 0.81 | FDPS (0.45) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL14864790 | 0.81 | FDPS (0.45) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL13179092 | 0.78 | FDPS (0.43) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL13748277 | 0.77 | FDPS (0.42) | FDPSNLRP3TSHRHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | FDPS 868/4885NLRP3 3035/4885TSHR 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.